851985-81-4

Usage

Uses

Used in Pharmaceutical Industry:
7-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)quinoline is used as a key intermediate in the synthesis of pharmaceutical compounds for its ability to facilitate the formation of complex molecular structures through carbon-carbon bond formation. Its role in creating new drugs and improving existing ones is crucial, as it can enhance the efficacy and selectivity of medicinal agents.
Used in Organic Synthesis:
In the realm of organic synthesis, 7-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)quinoline is used as a reagent for Suzuki-Miyaura cross-coupling reactions, which are essential for the creation of new organic molecules with specific properties. This application is vital for the development of advanced materials and compounds with tailored characteristics.
Used in Development of New Materials:
7-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)quinoline is utilized as a building block in the development of new materials, where its capacity to form carbon-carbon bonds is leveraged to create materials with unique properties. This is particularly relevant in the advancement of organic electronics, where novel materials with specific electronic characteristics are in high demand.
Used in Organic Electronics:
In the field of organic electronics, 7-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)quinoline is employed as a component in the design and synthesis of organic electronic devices. Its role in this industry is to contribute to the creation of organic semiconductors and other electronic components that can be used in flexible displays, solar cells, and other cutting-edge technologies.
Overall, 7-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)quinoline is a multifaceted chemical compound with broad applications across various industries, underscoring its importance in modern chemical research and development.

Upstream product

• 163485-84-5 7-quinolinyl trifluoromethanesulfonate 
• 73183-34-3 bis(pinacol)diborane 
• 4965-36-0 7-bromoquinoline 
• 580-20-1 quinolin-7-ol 

Downstream Products

• 889687-03-0 7-(4-fluorophenyl)quinoline hydrochloride 
• 29314-09-8 7-phenylquinoline 
• 25334-12-7 7-iodoquinoline 
• 1426049-99-1 2-(4-(quinolin-7-yl)phenyl)acetonitrile 
• 1426050-00-1 2-bromo-2-(4-(quinolin-7-yl)phenyl)acetonitrile 
• 1426095-62-6 2-[1-cyclopropylcarbonyl-3-azetidinyl]-N-[2-fluoro-4-(7-quinolinyl)phenyl]-N-methylacetamide 
• 1426095-60-4 2-[(3S)-1-cyclopropylcarbonyl-3-pyrrolidinyl]-N-[2-fluoro-4-(7-quinolinyl)phenyl]-N-methylacetamide 
• 1332333-06-8 (3S)-N-ethyl-3-({4-[2-fluoro-4-(7-quinolinyl)phenyl]-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl}methyl)-1-pyrrolidine carboxamide 
• 1332332-94-1 (3S)-N,N-dimethyl-3-({5-oxo-4-[4-(7-quinolinyl)phenyl]-4,5-dihydro-1H-1,2,4-triazol-3-yl}methyl)-1-pyrrolidinecarboxamide 
• 1332332-77-0 5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-4-[2-fluoro-5-methyl-4-(7-quinolinyl)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 1366767-62-5 7-[4-(4-{[1-(cyclopropylcarbonyl)-3-azetidinyl]methyl}-4H-1,2,4-triazol-3-yl)-3-fluorophenyl]quinoline 
• 1210047-83-8 methyl 2-((4-(quinolin-7-yl)-3-methyl-1-(2-methylphenyl)-1H-pyrazol-5-yl)amino)benzenecarboxylate 

Relevant academic research and scientific papers

ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS

Conjugate of a binder having formula: (A) wherein AB stands for a binder, Z' stands for a linker and D stands for an active component of Formula (I): and its use as pharmaceuticals.

Modular Synthesis of Di- A nd Trisubstituted Imidazoles from Ketones and Aldehydes: A Route to Kinase Inhibitors

A one-pot and modular approach to the synthesis of 2,4(5)-disubstituted imidazoles was developed based on ketone oxidation, employing catalytic HBr and DMSO, followed by imidazole condensation with aldehydes. This methodology afforded twenty-nine disubstituted NH-imidazoles (23%-85% yield). A three-step synthesis of 20 kinase inhibitors was achieved by employing this oxidation-condensation protocol, followed by bromination and Suzuki coupling in the imidazole ring to yield trisubstituted NH-imidazoles (23%-69%, three steps). This approach was also employed in the synthesis of known inhibitor GSK3037619A.

Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2

Provided herein are non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 and type 2 (17β-HSD1 and 17β-HSD2) inhibitors, their production and use, especially for the treatment and for prophylaxis of hormone-related diseases.

Heterocyclic compound with Wnt signal path inhibitory activity and application thereof

The invention provides a heterocyclic compound with Wnt signal path inhibitory activity. The heterocyclic compound and chemically acceptable salt, isotope, isomer and a crystal structure thereof are provided with a structure shown as the general formula I (see the formula in the description). The invention further provides application of the heterocyclic compound with the Wnt signal path inhibitory activity. The heterocyclic compound with the Wnt signal path inhibitory activity serves as effective antagonist of a Wnt signal path, and can be used for treating or preventing diseases caused by abnormity of the Wnt signal path.

FATTY ACID SYNTHASE INHIBITORS

This invention relates to novel spirocyclic piperidines according to Formula (I) which are inhibitors of fatty acid synthase (FAS), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

FATTY ACID SYNTHASE INHIBITORS

This invention relates to spirocyclic piperidines according to Formula (I) and the use of spirocyclic piperidines for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of spirocyclic piperidines in the treatment of cancer.

FATTY ACID SYNTHASE INHIBITORS

This invention relates to carboxamides and reverse carboxamides according to Formula (I) and the use of carboxamides and reverse carboxamides for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of carboxamides and reverse carboxamides in the treatment of cancer.

FATTY ACID SYNTHASE INHIBITORS

Disclosed are compounds having Formula (I), or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R5, R6, R7, R8, R8a, R9 Y, and m are defined herein and methods of using the same.

N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS

The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections. Formula (I).

SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF

The present application relates to novel substituted 5-aminopyrazoles, methods of production thereof, use thereof alone or in combinations for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases.